Corresponding figures for patients with thymoma treated with either anti-PD-1 (pembrolizumab) or anti-PD-L1 (avelumab) therapy are 0–25%, 17–43%, and 8–14% [40,41,42,43,44]. The gene discussed is CD274; the disease is thymoma.